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We investigated the preventive eﬀect of lycopene on nonalcoholic steatohepatitis-induced by high-fat diet in rats. Forty male
Sprague-Dawley rats were divided into 4 groups. They were fed standard diet, high-fat diet (HFD), high-fat diet plus lycopene
at a dose of 2mg/kg body weight and the high-fat diet lycopene at a dose of 4mg/kg BW for a period of 6 weeks. Inﬂammation,
steatosis, α-smooth muscle actin (α-SMA), and cytochrome P450 2E1 (CYP 2E1) expression increased signiﬁcantly in the rats fed
HFD and decreased in the rats administered by lycopene. Signiﬁcantly elevated levels of serum alanine aminotransferase (ALT),
aspartate aminotransferase (AST), tumor necrosis factor (TNF α), and serum and liver malondialdehyde (MDA) were observed
in rats fed the high-fat diet as compared to the control rats (P<. 01). Supplementation with lycopene lowered serum MDA and
tumor necrosis factor (TNF-α) levels and elevated liver GSH level (P<. 001). Insulin resistance was higher in the rats fed HFD
than in rats supplemented with lycopene. The data indicate that supplementation with lycopene can reduce high-fat diet-induced
oxidative stress to the cells.
1.Introduction
Nonalcoholic steatohepatitis (NASH) histologically resem-
bles alcoholic steatohepatitis. It is characterized by diﬀuse
fatty inﬁltration in the liver, and ballooning degenera-
tion and inﬂammation in the hepatocytes. Histopatholog-
ical signs may be accompanied by Mallory’s hyaline and
perisinusoidal ﬁbrosis [1–4]. There may be progression
to cirrhosis [5, 6]. Experimental model of NASH has
enabled the understanding of its pathogenesis. These were
induced in genetically obese ob/ob mice, lipoatrophic mice,
and experimental animals fed on methionine-deﬁcient diet
(MCD). All models appear to support multiple hit hypothe-
ses [7]. In the experimental models, steatosis is rapidly
formed in nonalcoholic fatty liver disease (NAFLD) models
induced in ob/ob mice (obese, and having dyslipidemia and
insulin resistant diabetes) and lipoatrophic rats, and with
methionine- and choline-deﬁcient diet. Its progression to
steatohepatitisandﬁbrosisishighlyvariable[8].Intheob/ob
mice model, there is only steatosis at the onset. Liver injury
emerges in case of leptin administration and/or exposure to
secondary harmful eﬀects. As ob/ob and lipoatrophic mice
have leptin deﬁciency, cirrhosis generally does not develop
in them. Methionine- and choline-deﬁcient diet leads to
steatohepatitis by reducing antioxidant defense systems and
increasing oxidative stress. There is a nutritional deﬁciency
in methionine- and choline-deﬁcient diet. However, there is
no such defect in human NAFLD. Human NAFLD is mostly
associated with obesity and diabetes. Therefore, the models
cited previously are not ideal experimental models.2 Veterinary Medicine International
High-fat diet (HFD) was seen to produce signs resem-
bling NASH in humans. In a standard diet, 35% of the
energy is procured from fat, 18% from protein, and 47%
from carbohydrate, while in HFD, 71% of the energy is
obtained from fat, 11% from carbohydrate, and 18% from
protein [9]. Peripheral insulin resistance, increased fatty acid
beta-oxidation, increase in oxidative stress in the liver, and
fatty degeneration in the liver are known characteristics of
NASH [3–6]. In a study with HFD, an increase in hepatic
TNFα,TNFαmRNA,oxidativestress,andcytochromeP450
mRNA levels were found together with histological signs of
steatohepatitis at the end of 3 weeks [9].
Lycopene is a carotenoid that is found abundantly in
tomatoes and has strong antioxidant characteristics [10,
11]. Previous studies showed that intake of tomatoes and
tomato products strengthened the antioxidant system, and
inhibited lipid peroxidation in humans [12]. Besides, it
was demonstrated that oral lycopene administration for 2
weeks inhibited lipid peroxidation in the liver tissues of
rats [13]. The objective of present study was to investigate
the protective eﬀect of lycopene on the development of
steatohepatitis in NASH model induced by HFD.
2.MaterialandMethod
2.1. Animals and Groups. Forty male Sprague-Dawley rats,
whichwerepurchasedfromFiratUniversity(Elazig,Turkey),
were maintained under controlled environmental conditions
(temperature 23 ± 2◦C, relative humidity 55%± 10%,
12/12 h light-dark cycle) and given food and water ad
libitum. All rats were acclimated for 1 week prior to the
e x p e r i m e n t .F o u rg r o u p so f1 0r a t se a c hw e r et r e a t e dw i t h
their respective group diet for 6 weeks. The control group
was fed a standard diet. The HFD group was fed a high-
fat liquid diet (HFD; using AIN76A diet as the base by
Dyets, Inc., Bethlehem, PA) with 71% of energy derived
from fat, 11% from carbohydrates, and 18% from protein.
The other two experimental groups were fed the same
high-fat diet with lycopene (DSM, Istanbul, Turkey) at a
dose of 2mg/kg body weight (HFD + 2mg/kg lycopene
group) and at a dose of 4mg/kg body weight (HFD +
4mg/kg lycopene group). Lycopene was administered by
gastric gavage mixed with olive oil and given 3 days per week.
The diets were isocaloric and isonitrogenic. This study and
all procedures were approved by the Animal Care and Use
Committee of Firat University, Turkey. The study lasted for
6 weeks, and the rats were sacriﬁced by decapitation. Liver
samples were collected from the animals for biochemical and
histopathological examination.
2.2. Plasma and Tissue MDA Measurements. Plasma MDA
levels were measured in accordance with thiobarbituric acid
method, modiﬁed by Yagi [14]. Results were presented as
nmol/mL. Liver tissue MDA levels were analyzed by Okhawa
method. Results were expressed as nmol/g tissue [15].
2.3. Glutathione Level. Determination of GSH was carried
out as described by Sedlak and Lindsay [16]. Results were
shown as μmol/mg tissue.
2.4. TNF-α Levels. TNF α was determined by using a
commercial kit (Biosoruce immunoassay kit, Biosource
international, Inc., CA., USA) in a spectrophotometer with
ELISA (ELx-800, Bio-Tek Instruments Inc., City, VT).
2.5. Biochemical Parameters. Blood samples collected from
the rats were centrifuged to obtain plasma, which was kept
at −20◦C until analysis. Insulin was analyzed using ELISA
method, while fasting blood glucose, alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), alkaline
phosphatase (ALP), gamma glutamyl peptidase (γ-GT),
triglyceride, and cholesterol levels were studied in Olympus
AU 600 autoanalyzer. Insulin resistance was calculated
according to the formula [17]. HOMA-IR: [serum glucose
level (mg/dL)/18.1xinsulin level (μIU/mL)]/22.5. A high
HOMA-IR score indicates high insulin resistance.
2.6. Histopathological Examination. Liver tissue samples
were stored in 10% formalin solution. Paraﬃn blocks were
prepared. Cross-sections obtained from the blocks were
stained with hematoxylin eosin and Masson’s trichrome.
Histopathological examination was carried out by a spe-
cialist pathologist. Steatohepatitis was diagnosed according
to Brunt’s histopathological criteria [4]. Histopathological
signs of steatosis, inﬂammation, and ﬁbrosis were scored
semiquantitatively and were modiﬁed from Brunt’s criteria
[18, 19]. Percentage of steatotic cells was determined. They
weregraded as+ up to 25%, ++ between 26% and 50%, +++
between 51% and 75%, and ++++ >76%. Inﬂammatory
cells were counted in randomly chosen 10 areas under
×400 magniﬁcation; the total number was divided by 10
to determine the mean number of inﬂammatory cells per
mm2. Necrosis was counted in randomly chosen 10 areas
under ×400 magniﬁcation, and the total was divided by ten
to determine the mean necrotic foci per mm2. Ballooning
degeneration and Mallory’s body were evaluated on the basis
of the presence/absence. Cross-sections taken from paraﬃn
blocks were stained with Mason’s Trichrome, and examined
under ×40, ×100, ×200, and ×400 magniﬁcation. Fibrosis
was staged between 0 and 4. Pericellular ﬁbrosis in Zone 3
stage 1; perivenular and pericellular ﬁbrosis in zone 2 and
3, irrespective of the presence of portal and/or periportal
ﬁbrosis stage 2; bridging ﬁbrosis stage 3; cirrhosis stage 4.
2.7.ImmunohistochemicalExamination. Immunohistochem-
ical α-smooth muscle actin (α-SMA) staining was conducted
in liver tissue to show hepatic stellate cell (HSC) activation
(Actin smooth muscle neomakers, catalogue no: RU-910-
R7). Presence of HSC reactive α-sMA in the liver was scored
semiquantitatively [20]. Grade 0: No or very rare staining,
grade 1: staining of <30% of stellate cells in sinusoidal liver
cells,grade2:stainingbetween31%and60%ofcells,grade3:
staining between 61% and 90% of cells, and grade 4: diﬀuse
staining in more than 90% of sinusoidal liver cells.
Immunohistochemicalstainingwasappliedtolivertissue
to show CYP2E1 expression (CYP2E1 Chemicon catalogue
no: AB1252). Zonal staining score was determined as
perivenular staining: 1, midzonal staining: 2, and panlobular
staining: 3. Severity of staining was evaluated as no staining:Veterinary Medicine International 3
0, mild staining: 1, moderate staining: 2, and severe staining:
3[ 21].
2.8. Statistical Evaluation. Data presented in the study were
shown as mean ± standard deviation, unless indicated
otherwise. Paired T test was used in the evaluation of data,
and Mann Whitney U test in double evaluations. Addition-
ally, Pearson Spearman correlation tests were employed for
some parameters. SPSS 11.0 package software was used in
statistical evaluations.
3. Results
Body and liver weights are presented in Table 1. The increase
in mean weight was signiﬁcant in the treatment groups
(HFD) in comparison to the control group (P<. 05 for
each). There was no signiﬁcant diﬀerence in liver weight
between the groups fed on the experimental diets for 6 weeks
(P>. 05, Table 1).
3.1. Biochemical Parameters. The serum activities of ALT,
AST, ALP, and levels of triglyceride and cholesterol in the
rats fed with HFD group were signiﬁcantly higher than
those in the control and the lycopene groups (P<. 05).
However, the increase in the activity of these enzymes was
markedly suppressed by supplementing lycopene (P<. 05,
Table 2) to the level of the normal control. However, the
supplementation level of lycopene did not result in dose-
dependency. ALT and triglyceride levels decreased when
compared to rats fed HFD (P<. 05 for each), while there
was no diﬀerence in AST, ALP, and cholesterol levels (P>
.05). ALT, AST, ALP, cholesterol, and triglyceride levels did
not change between rats fed HFD and supplemented with
diﬀerent dose of lycopene (P>. 05).
3.2. Oxidative Stress Measurement. Table 2 presents the
signiﬁcant increase in MDA level in serum and liver as a
result of lipid peroxidation in the HFD rats (P<. 001).
However, lycopene supplementation signiﬁcantly inhibited
this lipid peroxidation when compared to the HFD group
(P<. 01) and returned it to the level of the normal control
group. The MDA levels between the lycopene-supplemented
groups were not signiﬁcantly diﬀerent (P<. 001 for each,
Table 3). There was no signiﬁcant diﬀerence in the liver total
glutathione concentration between controland HFD groups.
However, lycopene supplementation tended to increase the
concentration of total glutathione (P<. 001, Table 3).
3.3.InsulinResistance. Insulinresistanceincreasedinratsfed
HFD, compared to the control rats (P<. 05), decreased
in rats administered lycopene at 2 or 4mg/kg level, but the
diﬀerence was not statistically signiﬁcant.
3.4. Serum TNF-α Level. The TNF-α level in the HFD group
was signiﬁcantly higher than that in the control (P<
.05, Table 2). However, the TNF-α level in the lycopene-
supplementedgroupswassigniﬁcantlylowerthanthelevelin




Figure 1: Histopathological ﬁndings in groups. (a) Normal liver
histology from liver section rat fed on standart diet (H&E ×
200). (b) Macro- and microvesicular steatosis and ballooning
degeneration around the central vein from liver section rat fed on
HFD (Hematoxylen-Eosin (H&E × 200). (c) The marked decreased
steatosis and inﬂammation from liver section rat fed on HFD +
lycopene (H&E × 200).
the control. However, the supplementation level of lycopene
did not signiﬁcantly aﬀect the TNF-α level.
3.5. Histopathological Examinations. Histopathological ﬁnd-
ings are presented in Table 4 and Figure 1. Steatosis, inﬂam-
mation, ballooning degeneration, and necrosis signiﬁcantly
increased rats fed HFD, compared to control. The diﬀerence
was in the increase in ﬁbrosis between control and HFD
groups were not signiﬁcant. Mallory’s hyaline was found
only in rats fed HFD (20%), but was not found in other4 Veterinary Medicine International
Table 1: The eﬀects of lycopene supplementation on body weight and liver weight in groups.
Weight Control group (n = 10) HFD (n =10) HFD + 2mg/kg lycopene (n = 9) HFD + 4mg/kg lycopene (n = 10)
Baseline BW 299,80 ±40,29 297,90 ±26,34 300,70 ± 30,22 298,20 ±27,89
Final BW 328,30 ±37.5 360,70 ±20,58∗∗ 364,30 ± 42,10 375,70 ±34,24∗
Liver weight (gr) 9,41 ±1,10 10,05 ±1,38 9,75 ±1,40 10,15 ±1,36
BW: body weight, ∗P<. 05: compared with HFD group; ∗∗P<. 05: compared with control.
Table 2: The eﬀects of lycopene on serum parameters in groups.
Parameter Control group (n = 10) HFD (n = 10) HFD + 2mg/kg lycopene (n = 9) HFD + 4mg/kg lycopene (n = 10)
Insulin (μIU/mL ) 0,129 ±0,069 0,132 ±0,028 0,116 ±0,340 0,102 ±0,0230
HOMA-R 0.032 ±0,02 0,043 ±0,02 0,036 ±0.01 0,034 ±0.06
Glucose (mg/dL) 127,33 ±12,30 139,11 ±9,25 130,22 ±8,89∗ 139,55 ±14,53
Triglyceride (mg/dL) 67,2±14,2 189,5 ±93,7† 157,3 ±56,8 130,9 ±33,3∗
Cholesterol (mg/dL) 49,80 ±5,76 71,7 ±6,2 78,4 ±20.2 71,0 ±5,18
ALT (IU/L) 84,1 ±7,3 96,2 ±11,4† 85,8 ±7,4∗ 81,2 ±15,7∗
AST (IU/L) 174,4 ±14,5 247,3 ±21,7† 231,7 ±38,5 238,0 ±20,16
ALP (IU/L) 213,3 ±63,7 467,3 ±87,9† 440,5 ±108,0 414,5 ±113,3
GGT (IU/L) 1,3 ±0,4 1,8 ±1,2 1.1 ± 0.60 1,7 ±0.9†
TNF-α (pg/mL) 0,192 ±0,50 0,615 ±0,358† 0,226 ±0,126∗ 0,254 ±0,186∗
∗P<. 05: compared with HFD group; †P<. 05: compared with control.
groups. Steatosis and inﬂammation in rats supplemented
with lycopene decreased compared to HFD rats (P<. 05).
The diﬀerence between HFD and HFD/lycopene (2mg/kg)
was not signiﬁcant for ballooning degeneration, ﬁbrosis, and
necrosis (P>. 05), nor there was any signiﬁcant diﬀerence
between lycopene doses.
3.6. Immunohistochemical Analysis. Immunohistochemical
analysis is presented in Figure 2. Expression of α-sMA and
CYP2E1 increased in rats fed HFD, compared to control rats
(P<. 001). CYP2E1 and α-sMA expression decreased in rats
fed HFD and lycopene at 2mg/kg, in comparison to rats
fed HFD (P<. 01); both α-sMA and CYP2E1 expression
signiﬁcantly decreased in rats fed HFD and lycopene at
4mg/kg, when compared to rats HFD (P<. 01). There was
no signiﬁcant diﬀerence between lycopene doses in terms
of α-sMA and CYP2E1 expression (P>. 05). There was a
positivecorrelationbetweenCYP2E1expression,andplasma
and liver tissue MDA increase (r = 0.704; P<. 001, r =
0.559; P<. 001, resp.). There was no signiﬁcant correlation
in terms of liver glutathione levels.
4. Discussion
Lycopene is the predominant carotenoid found in tomatoes
and tomato products [22, 23]. It has antioxidant and radical
oxygen scavenging eﬀects, through which it protects tissues
and cells against harmful eﬀects of free radicals [24, 25].
Consumption of large amounts of tomatoes was shown to
improve the antioxidant status and inhibit lipid peroxidation
[26]. The major organ where lycopene accumulates after
single dose 14C-lycopene administration is the liver [27].
Its level in liver tissues of rats orally fed on lycopene was
found to remain unchanged between 0.5g/kg and 5g/kg,
but directly increased from 0 to 5g/kg. It levels oﬀ in
concentrations dissolved in 10% water between 0.05g/kg
and 0.5g/kg [28]. In the present study, we found oral
lycopene administration to have a preventive eﬀect on the
development of steatohepatitis in rats in which experimental
NASHwasinduced.Weestablishedthatsteatosisandinﬂam-
mation were signiﬁcantly lower in lycopene-administered
rats, compared to the rats fed on an HFD alone. There
was not any diﬀerence between diﬀerent doses of lycopene.
This is the ﬁrst study examining the preventive role of
lycopene in experimental NASH model induced by HFD.
Oxidative stress plays a major role in the pathogenesis
of NASH [2, 8, 29]. Lipid peroxidation occurs through a
mechanism associated with free radicals. This process leads
to oxidative destruction of polyunsaturated fatty acids in
cellular membranes [30]. Lycopene administration brought
about a decrease in lipid peroxidation and an increase in
liver glutathione levels. Among carotenoids, lycopene has the
highest antioxidant capacity [31]. As a cellular antioxidant,
glutathione conjugates various electrophilic byproducts that
are able to initiate lipid peroxidation, and has the ability
to directly scavenge free radicals [32]. While preventing
oxidative stress by its free radical scavenging characteristic,
glutathione strengthens antioxidant defense systems.
High-fat diet intake is associated with increased oxida-
tive stress [9] and induction of the cytochrome P4502E1
(CYP2E1) enzyme [29, 33]. CYP2E1 has enhanced NADPH
oxidase activity resulting in increased production of the
reactive oxygen species superoxide and hydrogen peroxide
by redox cycling of endogenous and exogenous substrates
[33, 34]. The absence of antioxidants has been shown
to further promote high-fat diet-induced oxidative stress,Veterinary Medicine International 5
Table 3: The eﬀects of lycopene supplementation on MDA and glutathione levels in groups.
Parameter Control group (n = 10) HFD (n = 10) HFD + 2mg/kg lycopene (n = 9) HFD + 4mg/kg lycopene (n = 10)
Plasma MDA (nmol/mL) 2,06 ±0.54 4,28 ±0.94† 2,58 ±0,54∗ 2,12 ±0,51∗
Liver MDA (nmol/gr) 20,72 ±2.70 29,8 ±3,91† 20,21 ±4,39∗ 15,89 ±4,65∗
Liver glutathione (μmol/mg) 9,07 ± 1,01 8,08 ±1,19 22,62 ±20,09∗ 20,96 ±3,91∗





by rat fed on HFD + lycopene (d) (original magniﬁcation ×200).
which could lead to an inﬂammatory state. In the present
study,weobservedadecreasedCYP2E1proteinwithincreas-
ing lycopene dose in the high-fat diet rats. This decrease
was signiﬁcantly greater when lycopene was supplemented
at the high dose in rats compared with the rats that
were supplemented with the standard diet. Although the
mechanisms for these results are currently unknown, our
observation suggests that lycopene supplementation may
alleviate the harmful eﬀects of excessive high-fat diet intake.
Lycopene has been shown to act as an antioxidant depending
on the dose at which it is supplemented [23, 24]. Similarly,
Louisa et al. [35] reported that CYP2E1 probe enzyme
(p-nitrophenol hydroxylase) was signiﬁcantly reduced by
repeated administration of 100mg/kgBW/day lycopene. In a
study conducted with ethanol, ethanol caused an increase in
hydrogen peroxide and overexpression of CYP2E1, and this
increase was reduced by lycopene. Besides, glutathione levels
decreased, which was parallel to the increase in hydrogen
peroxide radicals [36]. In our study, CYP2E1 expression in
rats with induced NASH increased, and this increase was
inhibited by both doses of lycopene, as was the case in the
alcoholic model.
As HFD was continued for 6 weeks in the present study,
ﬁbrosis development in this period was minimal. Therefore,
evaluation in terms of ﬁbrosis was not adequate. Activation
ofHSC,whichhasthekeyroleinthedevelopmentofﬁbrosis,
was examined by showing sMA expression through the
immunohistochemical method. Lycopene was demonstrated
to inhibit HSCs in experimental liver ﬁbrosis model, and
to suppress ﬁbrogenesis [37]. It was seen in our study that
lycopene administration inhibited α-sMA expression, as in
liver ﬁbrosis model.6 Veterinary Medicine International
Table 4: The eﬀects of lycopene supplementation on histopathological changes.
Parameters Control group (n = 10) HFD (n = 10) HFD + 2mg/kg lycopene (n = 9) HFD + 4mg/kg lycopene (n = 10)
Steatosis (0–4) — 1,30+ 0,48† 0,6 ±0,51∗ 0,70 ±0,48∗
˙ Inﬂammation (cells/mm2)2 , 1 1 ±1,07 12,45 ±6,0† 4,50 ±2,1∗∗ 4,95,±3,81∗∗
Necrosis (foci/mm2) — 1,15 ±0,87† 0,72 ±0,24 0,57 ±0,38
Fibrosis (0–4) — 0,50 ±0,52† 0,60 ±0,51 0,20 ±0,42
CYP 2E1 expression 1,0 ±0,0 2,60 ±0,51† 1,70 ±0,48∗∗ 1,20 ±0,42∗∗
α-SMA expression — 2,50 ±0,52† 1,80 ±0,62∗ 1,40,±0,16∗∗
∗P<. 05: versus HFD group, ∗∗P<. 01: versus HFD group; versus HFD group, †P<. 01: versus control group.
Cytotoxic products of the lipid peroxidation can impair
cellular functions, nucleotide and protein synthesis, and can
have a part in liver ﬁbrogenesis by modulating collagen
genes in HSCs [38]. Most probably, lycopene suppresses
HSCactivationbyinhibitinglipidperoxidationviaitsspecial
free radical scavenging character. The primary metabolic
abnormality involved in the progression from fatty liver to
NASH is not known for sure. Insulin resistance plays a part
inthisprogression[2].Peripheralinsulinresistanceisamong
the well-known characteristics of NASH. NASH impairs the
inhibiting eﬀect of insulin on liver glucose output and its
other metabolic eﬀects. It leads to the activation of inhibitor
kappa kinase beta (IKK-β), and thereby causes peripheral
insulin resistance [39].
Many studies reported a central role of TNF-α and
other proinﬂammatory cytokines in the development of
obesity-associated insulin resistance and fatty liver [40, 41].
Schattenberg et al. [33] indicated that the presence of steato-
hepatitis result in the downregulation of insulin signaling,
potentially contributing to the insulin resistance associated
withnonalcoholicfattyliverdisease.High-fatdietintakealso
leads to the activation of several proinﬂammatory cytokines,
including TNF-a, and increased hepatic inﬁltration by
inﬂammatory cells [9, 33]. TNF-α is an important cytokine
in the development of many forms of liver injury, including
steatohepatitis [40]. The interaction between cytokines, and
oxidative stress and lipid peroxidation plays a key role in
the development of steatohepatitis [41]. TNF α, a signiﬁcant
mediator in insulin resistance, aﬀects the activity of tyrosine
kinase in insulin receptors [42]. In the present study, we have
shown that TNF-α level was reduced by the supplemental
lycopene, indicating that inﬂammation was prevented. The
groups that were administered lycopene also displayed a
decrease in insulin resistance, although the decrease was
not statistically signiﬁcant. Similar to our results, it is
reported that the adipose tissue secretes inﬂammatory
cytokines such as TNF-α by inducing insulin resistance
and upregulating the expression of other inﬂammatory
mediators [43]. Additionally, Herzog et al. [44]r e p o r t e d
that lycopene supplementation reduces transcript levels of
proinﬂammatory cytokines with downregulation of IL-6
expression.
In conclusion, lycopene has a preventive eﬀect on the
development of steatohepatitis in nonalcoholic steatohep-
atitis induced experimentally by HFD. This eﬀect can be
primarily explained by its antioxidant characteristic. There
is no diﬀerence between the oral administration of 2mg/kg
and 4mg/kg lycopene.
References
[1] J. Ludwig, T. R. Viggiano, D. B. McGill, and B. J. Ott,
“Non-alcoholic steatohepatitis. Mayo Clinic experiences with
a hitherto unnamed disease,” Mayo Clinic Proceedings, vol. 55,
no. 7, pp. 434–438, 1980.
[2] O. F. W. James and C. P. Day, “Non-alcoholic steatohepatitis
(NASH): a disease of emerging identity and importance,”
Journal of Hepatology, vol. 29, no. 3, pp. 495–501, 1998.
[3] C. A. Matteoni, Z. M. Younossi, T. Gramlich, N. Boparai,
Y. C. Liu, and A. J. McCullough, “Non-alcoholic fatty liver
disease: a spectrum of clinical and pathological severity,”
Gastroenterology, vol. 116, no. 6, pp. 1413–1419, 1999.
[ 4 ]E .M .B r u n t ,C .G .J a n n e y ,A .M .D iB i s c e g l i e ,B .A .
Neuschwander-Tetri, and B. R. Bacon, “Nonalcoholic steato-
hepatitis: a proposal for grading and staging the histological
lesions,” American Journal of Gastroenterology, vol. 94, no. 9,
pp. 2467–2474, 1999.
[5] V.Paradis,G.Perlemuter,F.Bonvoustetal.,“Highglucoseand
hyperinsulinemia stimulate connective tissue growth factor
expression: a potential mechanism involved in progression to
ﬁbrosis in nonalcoholic steatohepatitis,” Hepatology, vol. 34,
no. 4, pp. 738–744, 2001.
[6] S. A. Harrison, S. Torgerson, and P. H. Hayashi, “The
natural history of nonalcoholic fatty liver disease: a clinical
histopathologicalstudy,”AmericanJournalofGastroenterology,
vol. 98, no. 9, pp. 2042–2047, 2003.
[7] A. Koteish and A. M. Diehl, “Animal models of steatohepati-
tis,”BestPracticeandResearchinClinicalGastroenterology,vol.
16, no. 5, pp. 679–690, 2002.
[8] A. Koteish and A. M. Diehl, “Animal models of steatosis,”
Seminars in Liver Disease, vol. 21, no. 1, pp. 89–104, 2001.
[9] C. S. Lieber, M. A. Leo, K. M. Mak et al., “Model of
nonalcoholic steatohepatitis,” American Journal of Clinical
Nutrition, vol. 79, no. 3, pp. 502–509, 2004.
[10] D. Heber and Q.-Y. Lu, “Overview of mechanisms of action of
lycopene,” ExperimentalBiologyandMedicine,vol.227,no.10,
pp. 920–923, 2002.
[11] A. V. Rao, “Lycopene, tomatoes, and the prevention of
coronary heart disease,” Experimental Biology and Medicine,
vol. 227, no. 10, pp. 908–913, 2002.
[12] F. Visioli, P. Riso, S. Grande, C. Galli, and M. Porrini,
“Protective activity of tomato products on in vivo markers of
lipid oxidation,” European Journal of Nutrition,v o l .4 2 ,n o .4 ,
pp. 201–206, 2003.Veterinary Medicine International 7
[ 1 3 ]L .V .K r a v c h e n k o ,S .V .M o r o z o v ,N .A .B e k e t o v a ,V .P .
Deryagina, L. I. Avren’eva, and V. A. Tutel’yan, “Antioxidant
status of rats receiving lycopene in diﬀerent doses,” Bulletin of
Experimental Biology and Medicine, vol. 135, no. 4, pp. 353–
357, 2003.
[14] K. Yagi, “Assay for blood plasma or serum,” Methods in
Enzymology, vol. 105, pp. 328–331, 1984.
[15] H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides
in animal tissues by thiobarbituric acid reaction,” Analytical
Biochemistry, vol. 95, no. 2, pp. 351–358, 1979.
[16] J. Sedlak and R. H. Lindsay, “Estimation of total, protein-
bound, and nonprotein sulfhydryl groups in tissue with
Ellman’s reagent,” Analytical Biochemistry,v o l .2 5 ,n o .1 ,p p .
192–205, 1968.
[17] D. R. Matthews, J. P. Hosker, A. S. Rudenski et al., “Homeosta-
sis model assessment: insulin resistance and β-cell function
from fasting plasma glucose and insulin concentrations in
man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985.
[18] A. A. Nanji, E. K. Yang, F. Fogt, S. M. H. Sadrzadeh, and
A. J. Dannenberg, “Medium chain triglycerides and vitamin
E reduce the severity of established experimental alcoholic
liver disease,” Journal of Pharmacology and Experimental
Therapeutics, vol. 277, no. 3, pp. 1694–1700, 1996.
[19] R. Kirsch, V. Clarkson, E. G. Shephard et al., “Rodent
nutritional model of non-alcoholic steatohepatitis: species,
strain and sex diﬀerence studies,” Journal of Gastroenterology
and Hepatology, vol. 18, no. 11, pp. 1272–1282, 2003.
[ 2 0 ]D .T . - Y .L a u ,B .A .L u x o n ,S . - Y .X i a o ,M .R .B e a r d ,a n dS .
M. Lemon, “Intrahepatic gene expression proﬁles and alpha-
smooth muscle actin patterns in hepatitis C virus induced
ﬁbrosis,” Hepatology, vol. 42, no. 2, pp. 273–281, 2005.
[21] P. A. Cohen, K. M. Mak, A. S. Rosman et al., “Immunohis-
tochemical determination of hepatic cytochrome P-4502E1
in formalin-ﬁxed, paraﬃn-embedded sections,” Alcoholism:
Clinical and Experimental Research, vol. 21, no. 6, pp. 1057–
1062, 1997.
[22] L. A. Kaplan, J. A. Miller, E. A. Stein, and M. J. Stampfer,
“Simultaneous, high-performance liquid chromatographic
analysis of retinol, tocopherols lycopene, and α-a n dβ-
carotene in serum and plasma,” Methods in Enzymology, vol.
189, pp. 155–167, 1990.
[23] R. S. Parker, J. E. Swanson, C.-S. You, A. J. Edwards, and
T. Huang, “Bioavailability of carotenoids in human subjects,”
Proceedings of the Nutrition Society, vol. 58, no. 1, pp. 155–162,
1999.
[24] A. V. Rao, M. R. Ray, and L. G. Rao, “Lycopene,” Advances in
Food and Nutrition Research, vol. 51, pp. 99–164, 2006.
[25] W. Stahl, U. Heinrich, O. Aust, H. Tronnier, and H. Sies,
“Lycopene-rich products and dietary photoprotection,” Pho-
tochemical and Photobiological Sciences, vol. 5, no. 2, pp. 238–
242, 2006.
[ 2 6 ]V .J .P a r ﬁ t t ,P .R u b b a ,C .B o l t o n ,G .M a r o t t a ,M .H a r t o g ,a n d
M. Mancini, “A comparison of antioxidant status and free
radical peroxidation of plasma lipoproteins in healthy young
persons from Naples and Bristol,”European Heart Journal, vol.
15, no. 7, pp. 871–876, 1994.
[27] M. M. Mathews-Roth, S. Welankiwar, P. K. Seghal, N. C.
G. Lausen, M. Russett, and N. I. Krinsky, “Distribution of
[14C]canthaxanthinand[14C]lycopeneinratsandmonkeys,”
Journal of Nutrition, vol. 120, no. 10, pp. 1205–1213, 1990.
[28] T. W.-M. Boileau, S. K. Clinton, S. Zaripheh, M. H. Monaco,
S. M. Donovan, and J. W. Erdman Jr., “Testosterone and food
restriction modulate hepatic lycopene isomer concentrations
in male F344 rats,” J o u r n a lo fN u t r i t i o n , vol. 131, no. 6, pp.
1746–1752, 2001.
[29] M. D. Weltman, G. C. Farrell, P. Hall, M. Ingelman-Sundberg,
and C. Liddle, “Hepatic cytochrome P450 2E1 is increased
in patients with nonalcoholic steatohepatitis,” Hepatology, vol.
27, no. 1, pp. 128–133, 1998.
[30] K. H. Cheeseman, “Mechanisms and eﬀects of lipid peroxida-
tion,” Molecular Aspects of Medicine, vol. 14, no. 3, pp. 191–
197, 1993.
[31] P. Di Mascio, S. Kaiser, and H. Sies, “Lycopene as the
most eﬃcient biological carotenoid singlet oxygen quencher,”
Archives of Biochemistry and Biophysics, vol. 274, no. 2, pp.
532–538, 1989.
[32] K. A. Marrs, “The functions and regulation of glutathione s-
transferases in plants,” Annual Review of Plant Physiology and
Plant Molecular Biology, vol. 47, no. 1, pp. 127–158, 1996.
[33] J. M. Schattenberg, Y. Wang, R. Singh, R. M. Rigoli, and M.
J. Czaja, “Hepatocyte CYP2E1 overexpression and steatohep-
atitis lead to impaired hepatic insulin signaling,” Journal of
Biological Chemistry, vol. 280, no. 11, pp. 9887–9894, 2005.
[34] G. Ekstrom and M. Ingelman-Sundberg, “Rat liver microso-
mal NADPH-supported oxidase activity and lipid peroxida-
tion dependent on ethanol-inducible cytochrome P-450 (P-
450IIE1),” Biochemical Pharmacology, vol. 38, no. 8, pp. 1313–
1319, 1989.
[35] M. Louisa, F. D. Suyatna, A. Setiawati, and S. W. A. Jusman,
“TheeﬀectoflycopeneonthetotalcytochromeP450,CYP1A2
and CYP2E1,” Medical Journal of Indonesia, vol. 18, pp. 233–
238, 2009.
[36] Y. Xu, M. A. Leo, and C. S. Lieber, “Lycopene attenuates
alcoholic apoptosis in HepG2 cells expressing CYP2E1,”
Biochemical and Biophysical Research Communications, vol.
308, no. 3, pp. 614–618, 2003.
[37] Y. Kitade, S. Watanabe, T. Masaki, M. Nishioka, and H.
Nishino, “Inhibition of liver ﬁbrosis in LEC rats by a
carotenoid, lycopene, or a herbal medicine, Sho-saiko-to,”
Hepatology Research, vol. 22, no. 3, pp. 196–205, 2002.
[ 3 8 ]P .B e d o s s a ,K .H o u g l u m ,C .T r a u t w e i n ,A .H o l s t e g e ,a n dM .
Chojkier, “Stimulation of collagen α1 (I) gene expression is
associated with lipid peroxidation in hepatocellular injury: a
link to tissue ﬁbrosis?” Hepatology, vol. 19, no. 5, pp. 1262–
1271, 1994.
[ 3 9 ]M .Y u a n ,N .K o n s t a n t o p o u l o s ,J .L e ee ta l . ,“ R e v e r s a lo f
obesity- and diet-induced insulin resistance with salicylates or
targeted disruption of Ikkβ,” Science, vol. 293, no. 5535, pp.
1673–1677, 2001.
[40] D. B. Hill, S. Shedlofsky, C. J. McClain et al., “Cytokines and
liver disease,” in Cytokines in Healtth and Disease, D. Remick
and J. Friendland, Eds., pp. 401–425, Mercel Dekker, New
York, NY, USA, 2nd edition, 1997.
[41] L. Valenti, A. L. Fracanzani, P. Dongiovanni et al., “Tumor
necrosis factor α promoter polymorphisms and insulin resis-
tance innonalcoholic fattyliver disease,”Gastroenterology,vol.
122, no. 2, pp. 274–280, 2002.
[42] G. S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M. F.
White, and B. M. Spiegelman, “IRS-1-mediated inhibition
of insulin receptor tyrosine kinase activity in TNF-α-a n d
obesity-induced insulin resistance,” Science, vol. 271, no. 5249,
pp. 665–668, 1996.
[43] N. Markovits, A. B. Amotz, and Y. Levy, “The eﬀect of tomato-
derived lycopene on low carotenoids and enhanced systemic
inﬂammation and oxidation in severe obesity,” Israel Medical
Association Journal, vol. 11, no. 10, pp. 598–601, 2009.8 Veterinary Medicine International
[44] A. Herzog, U. Siler, V. Spitzer et al., “Lycopene reduced gene
expression of steroid targets and inﬂammatory markers in
normal rat prostate,” FASEB Journal, vol. 19, no. 2, pp. 272–
274, 2005.